- Home
- CSCI vs CANF Comparison
CSCI vs CANF Comparison
Compare CSCI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- CANF
- Stock Information
- Founded
- CSCI 1990
- CANF 1994
- Country
- CSCI Canada
- CANF Israel
- Employees
- CSCI N/A
- CANF N/A
- Industry
- CSCI
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- CANF Health Care
- Exchange
- CSCI NYSE
- CANF Nasdaq
- Market Cap
- CSCI 11.1M
- CANF 9.4M
- IPO Year
- CSCI 1996
- CANF N/A
- Fundamental
- Price
- CSCI $3.00
- CANF $1.55
- Analyst Decision
- CSCI
- CANF Strong Buy
- Analyst Count
- CSCI 0
- CANF 2
- Target Price
- CSCI N/A
- CANF $14.00
- AVG Volume (30 Days)
- CSCI 9.5K
- CANF 138.1K
- Earning Date
- CSCI 11-12-2024
- CANF 02-03-2025
- Dividend Yield
- CSCI N/A
- CANF N/A
- EPS Growth
- CSCI N/A
- CANF N/A
- EPS
- CSCI N/A
- CANF N/A
- Revenue
- CSCI $4,834,000.00
- CANF $667,000.00
- Revenue This Year
- CSCI N/A
- CANF $409.56
- Revenue Next Year
- CSCI N/A
- CANF N/A
- P/E Ratio
- CSCI N/A
- CANF N/A
- Revenue Growth
- CSCI N/A
- CANF N/A
- 52 Week Low
- CSCI $2.50
- CANF $1.29
- 52 Week High
- CSCI $11.10
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- CANF 43.14
- Support Level
- CSCI N/A
- CANF $1.55
- Resistance Level
- CSCI N/A
- CANF $1.64
- Average True Range (ATR)
- CSCI 0.00
- CANF 0.10
- MACD
- CSCI 0.00
- CANF 0.01
- Stochastic Oscillator
- CSCI 0.00
- CANF 17.14
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).